Scholarlink

<p>Sublingual administration of nicotinamide mononucleotide (NMN) is hypothesized to enhance systemic bioavailability by bypassing hepatic first-pass metabolism, a significant limitation of oral intake. However, direct comparative evidence in humans has been lacking. This study aimed to compare the acute pharmacokinetics of NMN following single-dose oral and sublingual administration in a randomized, two-period crossover trial involving 14 healthy adult males. Participants received NMN via both routes, separated by an 8-day washout period. Blood samples were collected for 60&#xa0;min post-administration to measure NMN and its metabolites, including nicotinamide (NAM), nicotinamide adenine dinucleotide (NAD⁺), and the terminal catabolites N1-methyl-2-pyridone-5-carboxamide (2PY) and N1-methyl-4-pyridone-3-carboxamide (4PY). The incremental area under the curve (iAUC) was significantly higher for the terminal metabolites 2PY and 4PY following sublingual administration compared to the oral route. In contrast, no significant differences were found for the blood concentrations of NMN, NAM, or NAD⁺ between methods. Both administration routes were well-tolerated, with no adverse events reported. These findings provide the first direct evidence in humans that sublingual administration leads to a more rapid increase in the terminal metabolites (2PY and 4PY) over 0–60&#xa0;min, although the metabolic origin of these increases could not be distinguished in the present study.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Sublingual NMN administration increases early circulating terminal catabolites 2PY and 4PY compared with oral administration in healthy adult men

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年6月16日

查看全文
  • Jun Wakabayashi,
  • Seiichiro Higashi,
  • Masashi Morifuji

摘要

Sublingual administration of nicotinamide mononucleotide (NMN) is hypothesized to enhance systemic bioavailability by bypassing hepatic first-pass metabolism, a significant limitation of oral intake. However, direct comparative evidence in humans has been lacking. This study aimed to compare the acute pharmacokinetics of NMN following single-dose oral and sublingual administration in a randomized, two-period crossover trial involving 14 healthy adult males. Participants received NMN via both routes, separated by an 8-day washout period. Blood samples were collected for 60 min post-administration to measure NMN and its metabolites, including nicotinamide (NAM), nicotinamide adenine dinucleotide (NAD⁺), and the terminal catabolites N1-methyl-2-pyridone-5-carboxamide (2PY) and N1-methyl-4-pyridone-3-carboxamide (4PY). The incremental area under the curve (iAUC) was significantly higher for the terminal metabolites 2PY and 4PY following sublingual administration compared to the oral route. In contrast, no significant differences were found for the blood concentrations of NMN, NAM, or NAD⁺ between methods. Both administration routes were well-tolerated, with no adverse events reported. These findings provide the first direct evidence in humans that sublingual administration leads to a more rapid increase in the terminal metabolites (2PY and 4PY) over 0–60 min, although the metabolic origin of these increases could not be distinguished in the present study.